Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today ...
GlobalData on MSN
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...
Investor's Business Daily on MSN
Alumis stock catapults more than 95% as biotech takes on J&J, Protagonist in psoriasis
Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...
A large, veteran enterprise in the healthcare sector is apparently interested in acquiring it. According to a media report, discussions on a deal are at an early stage. Image source: Getty Images.
Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback